S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Krystal Biotech Stock Forecast, Price & News

+0.05 (+0.07 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $69.62
50-Day Range
MA: $61.17
52-Week Range
Now: $69.62
Volume69,524 shs
Average Volume127,586 shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech logo


Overall MarketRank

1.53 out of 5 stars

Medical Sector

378th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

46th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:KRYS



Sales & Book Value

Annual SalesN/A
Book Value$11.72 per share


Net Income$-19,090,000.00


Market Cap$1.37 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
+0.05 (+0.07 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock been impacted by COVID-19 (Coronavirus)?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KRYS shares have increased by 39.5% and is now trading at $69.62.
View which stocks have been most impacted by COVID-19

Is Krystal Biotech a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Krystal Biotech's CEO?

1,448 employees have rated Krystal Biotech CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Krystal Biotech's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Krystal Biotech

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) issued its earnings results on Saturday, November, 14th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.02.
View Krystal Biotech's earnings history

What price target have analysts set for KRYS?

5 brokers have issued 12-month target prices for Krystal Biotech's shares. Their forecasts range from $84.00 to $115.00. On average, they expect Krystal Biotech's share price to reach $97.25 in the next year. This suggests a possible upside of 39.7% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view Wall Street analyst' top-rated stocks.

Who are some of Krystal Biotech's key competitors?

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan, Chairman, Pres & CEO (Age 56, Pay $365.73k)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 56, Pay $305.64k)
  • Ms. Pooja Agarwal, Sr. VP of Product Devel. (Age 42, Pay $259.58k)
  • Ms. Gloria Lin, Accounting Mang.
  • Ms. Kathryn A. Romano, Chief Accounting Officer (Age 40)
  • Mr. J. Christopher Naftzger, Chief Legal Officer & Corp. Sec. (Age 54)
  • Mr. John Karakkal, VP of North American Sales and Marketing
  • Ms. Katherine Tuminello, HR & Office Mang.
  • Mr. Josh Suskin, Director of HR & Operations
  • Ms. Whitney Glad Ijem, Sr. VP of Strategy & Bus. Devel.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.11%), Liberty One Investment Management LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Krystal Biotech
or view top insider-selling stocks.

Which major investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Liberty One Investment Management LLC.
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $69.62.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $1.37 billion. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 51 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.